<ul>
<li>Guardant Health（纳斯达克股票代码：GH）与演员及癌症倡导者帕特里克·登普西合作，提高对结直肠癌筛查及其 FDA 批准的 Shield 血液检测的认识。</li>
<li>该公司还同意收购 MetaSight Diagnostics，增加旨在早期疾病检测的下一代液体活检技术。</li>
</ul>
<p>Guardant Health 是一家在纳斯达克上市的精准肿瘤学公司，专注于基于血液的癌症筛查、治疗选择和疾病监测测试。与帕特里克·登普西的合作为结直肠癌筛查选项带来了更多关注，包括 Guardant Health 的 Shield 血液检测。早期检测仍然是一个重要的健康优先事项，提高公众意识可以成为测试逐步采用的重要因素。</p>
<p>收购 MetaSight Diagnostics 为 Guardant Health 的工具箱增加了使用液体活检方法进行更早和更精确的疾病检测。随着公司整合 MetaSight 的技术和研究管道，投资者可以关注 Guardant Health 如何在未来几年内定位其扩展的检测组合，包括筛查、诊断和治疗决策支持。</p>
<p>通过将 Guardant Health 添加到您的关注列表或投资组合，随时了解 Guardant Health 最重要的新闻故事。或者，探索我们的社区，发现关于 Guardant Health 的新视角。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTAzLTA0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTAzLTA0"/></p>
<p>截至 2026 年 3 月的纳斯达克股票代码：GH 的收益与收入增长</p>
<p>📰 超越标题：Guardant Health 面临的 3 个风险和 3 个积极因素，每位投资者都应关注。</p>
<h3>快速评估</h3>
<ul>
<li><strong>✅ 价格与分析师目标</strong>：当前股价为 93.30 美元，低于 132.57 美元的共识目标，约低 30%。</li>
<li><strong>✅ Simply Wall St 估值</strong>：该股票被评估为低估，交易价格大约低于估计公允价值的 37.5%。</li>
<li><strong>❌ 最近的动能</strong>：30 天的回报约为 18.2% 的下降，显示市场在短期内持谨慎态度。</li>
</ul>
<p>了解何时买入、卖出或持有 Guardant Health 的唯一方法是查看 Simply Wall St 的公司报告，以获取 Guardant Health 公允价值的最新分析。</p>
<h3>关键考虑因素</h3>
<ul>
<li>📊 帕特里克·登普西的合作和 MetaSight 交易都进一步推动了 Guardant 在早期检测和筛查方面的发展，这正是其基于血液的检测重点所在。</li>
<li>📊 关注 Shield 血液检测的采用情况、MetaSight 液体活检技术的整合进展，以及这些如何影响收入和利润趋势。</li>
<li>⚠️ 该公司目前处于亏损状态，股东权益为负，并被标记为盈利风险，因此资金需求和资产负债表的强度仍然是关键关注点。</li>
</ul>
<h3>深入了解</h3>
<p>要获取完整的风险和收益信息，请查看 Guardant Health 的完整分析。或者，您可以访问 Guardant Health 的社区页面，了解其他投资者如何看待这一最新消息将如何影响公司的叙述。</p>
<p><em>本文由 Simply Wall St 撰写，内容为一般性信息。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：在一个地方管理您的所有股票投资组合</strong></h3>
<p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>并且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

<p>Guardant Health 与演员 Patrick Dempsey 合作，推广结直肠癌筛查及其 Shield 血液检测。该公司还收购了 MetaSight Diagnostics，以增强其液体活检技术，以便早期疾病检测。这一合作旨在提高癌症筛查的意识和采用率。投资者应关注 MetaSight 技术的整合及 Shield 检测的表现，因为 Guardant Health 面临盈利风险，目前处于亏损状态。该股票被认为被低估，交易价格低于分析师目标</p>

<ul>
<li>Guardant Health (NasdaqGS:GH) partnered with actor and cancer advocate Patrick Dempsey to raise awareness of colorectal cancer screening and its FDA approved Shield blood test.</li>
<li>The company also agreed to acquire MetaSight Diagnostics, adding next generation liquid biopsy technology aimed at early disease detection.</li>
</ul>
<div class="lb-trans"><ul>
<li>Guardant Health（纳斯达克股票代码：GH）与演员及癌症倡导者帕特里克·登普西合作，提高对结直肠癌筛查及其 FDA 批准的 Shield 血液检测的认识。</li>
<li>该公司还同意收购 MetaSight Diagnostics，增加旨在早期疾病检测的下一代液体活检技术。</li>
</ul>
</div><p>Guardant Health, a precision oncology company listed on NasdaqGS:GH, focuses on blood based tests for cancer screening, treatment selection and disease monitoring. The collaboration with Patrick Dempsey brings additional attention to colorectal cancer screening options, including Guardant Health’s Shield blood test. Early detection remains a major health priority, and higher public awareness can be an important ingredient for test adoption over time.</p>
<div class="lb-trans"><p>Guardant Health 是一家在纳斯达克上市的精准肿瘤学公司，专注于基于血液的癌症筛查、治疗选择和疾病监测测试。与帕特里克·登普西的合作为结直肠癌筛查选项带来了更多关注，包括 Guardant Health 的 Shield 血液检测。早期检测仍然是一个重要的健康优先事项，提高公众意识可以成为测试逐步采用的重要因素。</p>
</div><p>The MetaSight Diagnostics acquisition adds to Guardant Health’s toolkit for earlier and more refined detection of disease using liquid biopsy approaches. As the company integrates MetaSight’s technology and research pipeline, investors may monitor how Guardant Health positions its expanded testing portfolio across screening, diagnostics and treatment decision support in the coming years.</p>
<div class="lb-trans"><p>收购 MetaSight Diagnostics 为 Guardant Health 的工具箱增加了使用液体活检方法进行更早和更精确的疾病检测。随着公司整合 MetaSight 的技术和研究管道，投资者可以关注 Guardant Health 如何在未来几年内定位其扩展的检测组合，包括筛查、诊断和治疗决策支持。</p>
</div><p>Stay updated on the most important news stories for Guardant Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Guardant Health.</p>
<div class="lb-trans"><p>通过将 Guardant Health 添加到您的关注列表或投资组合，随时了解 Guardant Health 最重要的新闻故事。或者，探索我们的社区，发现关于 Guardant Health 的新视角。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTAzLTA0" alt="" original-src="https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/earnings-and-revenue-growth?date=2026-03-04"/></p>
<p>NasdaqGS:GH Earnings &amp; Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月的纳斯达克股票代码：GH 的收益与收入增长</p>
</div><p>📰 Beyond the headline: 3 risks and 3 things going right for Guardant Health that every investor should see.</p>
<div class="lb-trans"><p>📰 超越标题：Guardant Health 面临的 3 个风险和 3 个积极因素，每位投资者都应关注。</p>
</div><h3>Quick Assessment</h3>
<div class="lb-trans"><h3>快速评估</h3>
</div><ul>
<li><strong>✅ Price vs Analyst Target</strong>: At US$93.30 versus a consensus target of US$132.57, shares sit about 30% below where analysts as a group think the price could reasonably be.</li>
<li><strong>✅ Simply Wall St Valuation</strong>: The stock is assessed as undervalued, trading roughly 37.5% below the estimated fair value.</li>
<li><strong>❌ Recent Momentum</strong>: The 30 day return of about 18.2% decline shows the market has been cautious in the short term.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>✅ 价格与分析师目标</strong>：当前股价为 93.30 美元，低于 132.57 美元的共识目标，约低 30%。</li>
<li><strong>✅ Simply Wall St 估值</strong>：该股票被评估为低估，交易价格大约低于估计公允价值的 37.5%。</li>
<li><strong>❌ 最近的动能</strong>：30 天的回报约为 18.2% 的下降，显示市场在短期内持谨慎态度。</li>
</ul>
</div><p>There is only one way to know the right time to buy, sell or hold Guardant Health. Head to Simply Wall St's company report for the latest analysis of Guardant Health's fair value.</p>
<div class="lb-trans"><p>了解何时买入、卖出或持有 Guardant Health 的唯一方法是查看 Simply Wall St 的公司报告，以获取 Guardant Health 公允价值的最新分析。</p>
</div><h3>Key Considerations</h3>
<div class="lb-trans"><h3>关键考虑因素</h3>
</div><ul>
<li>📊 The Patrick Dempsey partnership and MetaSight deal both push Guardant further into early detection and screening, which sit at the core of its blood based testing focus.</li>
<li>📊 Keep an eye on adoption of the Shield blood test, integration progress for MetaSight's liquid biopsy technology and how these feed into revenue and margin trends.</li>
<li>⚠️ The company is currently loss making with negative shareholders' equity and has been flagged for profitability risks, so funding needs and balance sheet strength remain key watchpoints.</li>
</ul>
<div class="lb-trans"><ul>
<li>📊 帕特里克·登普西的合作和 MetaSight 交易都进一步推动了 Guardant 在早期检测和筛查方面的发展，这正是其基于血液的检测重点所在。</li>
<li>📊 关注 Shield 血液检测的采用情况、MetaSight 液体活检技术的整合进展，以及这些如何影响收入和利润趋势。</li>
<li>⚠️ 该公司目前处于亏损状态，股东权益为负，并被标记为盈利风险，因此资金需求和资产负债表的强度仍然是关键关注点。</li>
</ul>
</div><h3>Dig Deeper</h3>
<div class="lb-trans"><h3>深入了解</h3>
</div><p>For the full picture including more risks and rewards, check out the complete Guardant Health analysis. Alternatively, you can visit the community page for Guardant Health to see how other investors believe this latest news will impact the company's narrative.</p>
<div class="lb-trans"><p>要获取完整的风险和收益信息，请查看 Guardant Health 的完整分析。或者，您可以访问 Guardant Health 的社区页面，了解其他投资者如何看待这一最新消息将如何影响公司的叙述。</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容为一般性信息。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：在一个地方管理您的所有股票投资组合</strong></h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>并且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

Guardant Health Targets Early Detection Growth With New Partner And Acquisition

Simplywall

基因改革 ETF - ARK

美国医疗保健供应商 ETF - iShares

标普生物技术 ETF - SPDR

基因免疫&健康关怀 ETF - iShares

医疗业 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国医药设备 ETF - iShares

Guardant Health

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

Guardant Health 通过新的合作伙伴关系和收购，目标是推动早期检测领域的增长